Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804222 | 0.87 | ALDH1A1 (0.42) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL6805138 | 0.85 | RAB9A (0.50) | RAB9ANPC1L3MBTL1THRBHPGD | |
| SCHEMBL29806039 | 0.81 | L3MBTL1 (0.51) | L3MBTL1GRM5USP30LMNAF10 | |
| SCHEMBL6804420 | 0.76 | USP30 (0.47) | L3MBTL1GRM5USP30LMNAF10 | |
| SCHEMBL6802371 | 0.73 | MAPT (0.45) | RAB9ANPC1L3MBTL1THRBHPGD | |
| SCHEMBL7579004 | 0.72 | ALDH1A1 (0.49) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL6229771 | 0.71 | ALDH1A1 (0.48) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL29806150 | 0.69 | L3MBTL1 (0.50) | L3MBTL1USP30LMNAF10TSHR | |
| SCHEMBL29805990 | 0.69 | L3MBTL1 (0.50) | L3MBTL1USP30LMNAF10TSHR | |
| SCHEMBL29806203 | 0.67 | MAPK1 (0.47) | L3MBTL1USP30LMNAF10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689793-B2 | INHIBITORS OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE AND MULTI-DRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS REVERSE TRANSCRIPTASE | PARKER HUGHES INSTITUTE | 2004-02-10 | — | — | US | claimed |
| US-20020151568-A1 | Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity | PARKER HUGHES INSTITUTE | 2002-10-17 | — | — | US | claimed |
| US-6689793-B2 | INHIBITORS OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE AND MULTI-DRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS REVERSE TRANSCRIPTASE | PARKER HUGHES INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| US-20020151568-A1 | Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity | PARKER HUGHES INSTITUTE | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151568-A1 | Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity | SAMHD1, PNP, NUDT1 | RAB9A 2832/4885NPC1 444/4885L3MBTL1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.